Home Health News Novel Drug for HER2-Mutant Lung Cancer Wins FDA Approval By News Health 7 hours Ago Share on FacebookShare on Twitter (MedPage Today) — The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations. Approval of the tyrosine… Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116921 Author : Publish date : 2025-08-08 21:19:00 Copyright for syndicated content belongs to the linked Source. Categories: Health News Related Content CDC Buildings Hit by Gunfire By News Health August 9, 2025 Oddly viscous stars could be impersonating black holes By News Health August 8, 2025 Trump Order Gives Political Appointees Review of Scientific Grants By News Health August 8, 2025 Brain Autopsies Suggest MIND Diet Reduces Pathology By News Health August 8, 2025 FDA Restricts Gene Therapy Skysona Due to Blood Cancer Risk By News Health August 8, 2025 FDA Approves Zongertinib for HER2-Mutated NSCLC By News Health August 8, 2025